Related Experiment Video
Updated: May 24, 2026
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Ventilator-associated pneumonia: a review
Madiha Ashraf1, Luis Ostrosky-Zeichner
1Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX 77030, USA. madiha.ashraf@uth.tmc.edu
Abstract:
Ventilator-associated pneumonia (VAP) is the most common infection seen in intensive care units (ICUs); it accounts for one-fourth of the infections occurring in critically ill patients and is the reason for half of antibiotic prescriptions in mechanically ventilated patients. In addition to being a financial burden on ICUs, it continues to contribute significantly to the morbidity and mortality of ICU patients, with an estimated attributable mortality rate of 8% to 15%. While the pathophysiology of VAP remains relatively unchanged, diagnostic techniques and preventive measures are constantly evolving. The focus of this article is on recent trends in VAP epidemiology, modifiable risk factors, diagnostic techniques, challenges in management, and current data on the prevention of VAP. Important messages that the reader should take away include: 1) There is no gold standard for the diagnosis of VAP; whenever VAP is suspected, if feasible, a quantitative culture should be obtained by invasive or noninvasive methods (whichever is more readily available before initiation of antibiotics); 2) Suspicion based on clinical features should prompt the initiation of a broad spectrum of antibiotics depending on suspected pathogens; 3) Close attention should be paid to de-escalation of antibiotics once microbiological results become available or as the patient starts responding clinically; the ideal duration of treatment should be 8 days instead of the conventional 10 to 14 days, except in situations where Pseudomonas may be suspected or the patient's comorbidities dictate otherwise; and 4) Prevention remains the key to reducing the burden of VAP. We promote the proven preventive measures of using noninvasive ventilation when possible, semirecumbent patient positioning, continuous aspiration of subglottic secretions, and oral chlorhexidine washes along with stress ulcer prophylaxis only after careful assessment of the risks versus benefits.
Insights
Ventilator-associated pneumonia (VAP) is a common ICU infection. Early diagnosis, appropriate antibiotic use with de-escalation, and proven preventive strategies are crucial for reducing VAP
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pulmonology
Background:
- Ventilator-associated pneumonia (VAP) is the most frequent intensive care unit (ICU) infection, causing significant morbidity, mortality, and increased antibiotic use.
- VAP contributes to 25% of ICU infections and 50% of antibiotic prescriptions in mechanically ventilated patients, imposing a substantial financial burden.
- Attributable mortality for VAP ranges from 8% to 15%, highlighting the critical need for effective management and prevention strategies.
Purpose of the Study:
- To review recent advancements in VAP epidemiology, risk factors, diagnostics, and management.
- To emphasize evolving diagnostic techniques and preventive measures for VAP.
- To provide actionable insights for healthcare professionals managing VAP in ICUs.
Main Methods:
- Review of current literature on VAP epidemiology and trends.
- Analysis of modifiable risk factors associated with VAP development.
- Evaluation of contemporary diagnostic approaches and treatment guidelines.
- Assessment of evidence-based preventive strategies for VAP.
Main Results:
- No definitive gold standard exists for VAP diagnosis; quantitative cultures are recommended before antibiotic initiation.
- Empirical broad-spectrum antibiotic therapy is advised upon suspicion, followed by de-escalation based on results or clinical response.
- Optimal antibiotic treatment duration is suggested at 8 days, with exceptions for specific pathogens or comorbidities.
- Proven preventive measures include noninvasive ventilation, semirecumbent positioning, subglottic secretion drainage, and chlorhexidine oral care.
Conclusions:
- Effective VAP management requires a multi-faceted approach encompassing timely diagnosis, judicious antibiotic use, and de-escalation.
- Preventive strategies are paramount in reducing the incidence and impact of VAP in critically ill patients.
- Adherence to evidence-based preventive measures can significantly decrease VAP-associated morbidity and mortality.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:30Pneumonia III: Complications and Assessment
01:29Pneumonia II: Pathophysiology
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: